`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MEDTRONIC, INC.
`Petitioner
`
`v.
`
`NUVASIVE, INC.
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2013-00506
`Patent 8,361,156
`
`
`
`
`
`
`
`
`
`
`
`
`
`MOTION FOR OBSERVATION REGARDING CROSS-EXAMINATION
`
`OF LOIC JOSSE
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`
`
`
`
`EXHIBITS
`
`Ex. #
`
`Exhibit Description
`
`NUVA 2101 U.S. Patent No. 7,905,840 to Pimenta et al.
`NUVA 2102 Declaration in Support of the Pro Hac Vice Admission of Michael
`A. Amon; Declaration of Charles Forthaus (Not Filed)
`
`NUVA 2103 Vetebral Spacer-PR Brochure (Not Filed)
`NUVA 2104 Forthaus Memo regarding Vertebral Spacer-PR Brochure (Not
`Filed)
`
`NUVA 2105 myspinetools.com front page (Not Filed)
`
`NUVA 2106 myspinetools.com Terms of Use (Not Filed)
`
`NUVA 2107 Launch Binder (Not Filed)
`
`NUVA 2108 Webpage Toad MySQL (Not Filed)
`
`NUVA 2109 Reserved
`
`NUVA 2010 U.S. Patent 8,512,408 (Hynes) (Not Filed)
`
`NUVA 2011 Synthes SVS-PR Guide
`
`NUVA 2012 Medtronic Sofamor Danek Boomerang brochure
`
`NUVA 2013 Hynes Deposition Transcript
`
`NUVA 2014 510(k) Summary Medtronic Sofamor Danek K122037
`
`NUVA 2015 510(k) Summary Telamon® PEEK Spinal System K110562
`
`NUVA 2016 Synthes Vertebral Spacer – AR Brochure
`
`NUVA 2017 DePuy Spine Saber Surgical Technique Brochure
`
`NUVA 2018 Declaration of Barton L. Sachs, M.D. in IPR2013-00206
`
`2
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`NUVA 2019 Moro, et al., “An Anatomic Study of the Lumbar Plexus with
`Respect to Retroperitoneal Endoscopic Surgery”
`
`NUVA 2020 Declaration of Dr. Hansen A. Yuan, M.D.
`
`NUVA 2021 Curriculum Vitae of Dr. Hansen A. Yuan, M.D.
`
`NUVA 2022 NuVasive - CoRoent XL Brochure
`
`NUVA 2023 Redacted Engineering Drawings
`
`NUVA 2024 Redacted Deposition of Steven DeRidder
`
`NUVA 2025 Clydesdale® Spinal System Brochure
`
`NUVA 2026 Clydesdale® Spinal System Images
`NUVA 2027 Medtronic Direct Lateral Interbody Fusion DLIF Surgical
`Technique Brochure
`
`NUVA 2028 Medtronic DILF-Direct Lateral Interbody Fusion Brochure
`
`NUVA 2029 Clydesdale® Spinal System Image
`
`NUVA 2030 Declaration of Patrick Miles
`
`NUVA 2031 Declaration of Theodore G. Obenchain, M.D.
`NUVA 2032 The Relationship between Cross Sectional Area and Strength of
`Back Muscles in Patients with Chronic Low Back Pain
`
`NUVA 2033 Printout, U.S. News & World Report
`
`NUVA 2034 Lumbar Vertebral Body Replacement
`
`NUVA 2035 Lumbar – Minimally Invasive Approach (PLIF)
`NUVA 2036 Excerpts from the Mathews Deposition Transcript (non-
`confidential portion)
`
`NUVA 2037 Second Hynes Deposition Transcript
`
`NUVA 2038 Josse Deposition Transcript
`
`3
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`NUVA 2039 Patent Owner’s Objection to Evidence Under 37 CFR §
`42.64(b)(1), dated 9/12/2014
`
`NUVA 2040 Email from Michael A. Amon to Jeff E. Schwartz, dated 9/9/2014
`
`4
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`
`
`
`NuVasive, Inc. (“Patent Owner”) submits this motion for observation regarding
`
`cross-examination of Loic Josse, a reply declarant of Medtronic, Inc.
`
`(“Petitioner”). Patent Owner submits the following observations based on Mr.
`
`Josse’s testimony taken on September 23, 2014.
`
`Observation #1
`
`In Ex. 2038, on page 55 lines 13-25, Mr. Josse testified regarding the engineering
`
`drawings that he created, and stated that he did not add black redaction boxes to
`
`the engineering drawings and that the document existed without black boxes at
`
`least in 2013. That testimony is relevant to ¶ 2 of the Josse Declaration (Ex. 1116)
`
`where he references “engineering drawings that I created in January 2000.” The
`
`testimony is relevant because the heavily redacted Appendix A is not a true and
`
`correct copy of the engineering drawings that Mr. Josse actually created.
`
`Observation #2
`
`In Ex. 2038, on page 59, line 20 to page 60, line 11, Mr. Josse testified regarding
`
`an email string that he was copied on, and stated that he did not add black
`
`redaction boxes to the email string and that the document existed without black
`
`boxes at least at least in 2012. That testimony is relevant to ¶ 2 of the Josse
`
`Declaration where he references an “email string, on which I was copied.” The
`
`5
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`testimony is relevant because the heavily redacted Appendix B is not a true and
`
`correct copy of the email string on which Mr. Josse was actually copied.
`
`Observation #3
`
`In Ex. 2038, page 32, line 7 to page 33, line 18, Mr. Josse testified that his patent
`
`in Appendix E to his Declaration does not state that the implant has a length
`
`exceeding 40 mm. That testimony is relevant to ¶ 4 of the Josse Declaration where
`
`he states that “Medtronic has commercialized interbody spinal fusion implants
`
`having a length of at least 40 mm”. Ex. 1116 at ¶ 4. Nothing in Mr. Josse’s
`
`testimony indicates that the reference teaches a length meeting the claim language
`
`of “greater than 40 mm extending from a proximal end of said proximal wall to a
`
`distal end of said distal wall.” Nothing in Mr. Josse’s testimony indicates that the
`
`reference teaches a length meeting the claim language of “greater than 40 mm
`
`extending from a proximal end of said proximal wall to a distal end of said distal
`
`wall,” much less that any implant greater than 40mm was actually commercialized.
`
`Observation #4
`
`In Ex. 2038, on page 37, line 9 to page 38, line 11, Mr. Josse testified “I don’t have
`
`an opinion. I don’t know.” on whether the brochure in Appendix D to his
`
`declaration discloses an implant exceeding 40 mm. That testimony is relevant to ¶
`
`4 of the Josse Declaration where he states that “Medtronic has commercialized
`
`interbody spinal fusion implants having a length of at least 40 mm”. Ex. 1116 at ¶
`
`6
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`4. Nothing in Mr. Josse’s testimony indicates that the reference teaches a length
`
`meeting the claim language of “greater than 40 mm extending from a proximal end
`
`of said proximal wall to a distal end of said distal wall,” much less that any implant
`
`greater than 40mm was actually commercialized.
`
`Observation #5
`
`In Ex. 2038, on page 43, lines 6-22, Mr. Josse testified that the implant in the
`
`brochure in Appendix D to his declaration is marked “Not for distribution in the
`
`United States,” “Draft Copy,” and “for internal use only.” That testimony is
`
`relevant to the ¶ 4 of the Josse Declaration where he suggests that the document
`
`was publicly known. The testimony shows that Appendix D was an internal, draft
`
`brochure that is not a public document and not printed prior art.
`
`Observation #6
`
`In Ex. 2038, on page 44, line 16 to page 45, line 17, Mr. Josse testified that he
`
`included no bill of sale for a Butterfly implant, no surgical report for use of a
`
`Butterfly implant in a live patient, and no testimony in his declaration that
`
`indicates that a Butterfly implant was used in the United States. See also Ex. 2038,
`
`Page 43, lines 6-10. That testimony is relevant to the ¶ 4 of the Josse Declaration
`
`where he suggests that the Butterfly implant described in Appendix D was
`
`commercialized. The testimony confirms that there is no evidence of if or when
`
`7
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`the Butterfly implant was on sale or even used in the United States. See also 35
`
`U.S.C. § 102(b) (Pre-AIA).
`
`Observation #7
`
`In Ex. 2038, on page 73, lines 2-17, Mr. Josse testified to the dimension “D” in
`
`Appendix D as being the “width” of a boomerang implant. That testimony is
`
`relevant because it contradicts Petitioner’s argument in the IPR2013-00507
`
`Petition, p. 21-22 regarding the maximum lateral width of the boomerang implant
`
`in Frey. Specifically, Mr. Josse’s testimony directly contradicts Petitioner’s
`
`assertion that the implant disclosed in Frey meets the claim limitation of “said
`
`longitudinal length [that] is at least two and half times greater than the maximum
`
`lateral width” in claim 1 of the ‘334 patent.
`
`Observation #8
`
`In Ex. 2038, on page 74, line 4 to page 76, line 3, Mr. Josse testified that he has
`
`“no opinion” on whether a boomerang implant with a length of 41 mm and a width
`
`of 18 mm has a maximum length at least 2.5 times greater than the maximum
`
`width. That testimony is relevant to argument in the IPR2013-00507 Petition, p.
`
`21-22 and 52-55 that a boomerang implant should be sized to have a length that is
`
`over 40 mm and that is at least two and half times the maximum lateral width. The
`
`testimony shows that even the unpublished, unused boomerang implant identified
`
`in Appendices A-C to the Josse Declaration does not meet the claim limitation of
`
`8
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`“said longitudinal length [that] is at least two and half times greater than the
`
`maximum lateral width” in claim 1 of the ‘334 patent. It also calls into question
`
`the credibility of Mr. Josse – a trained engineer who has been designing implants
`
`for the last 20 years – yet was unwilling to answer a simple math problem.
`
`Observation #9
`
`In Ex. 2038, on page 77, line 16 to page 78, line 8, Mr. Josse testified there that
`
`there is no documentation or other evidence, including testimony, that a
`
`confidential prototype boomerang implant of the identified dimensions was ever
`
`actually used in any patient, much less that it was used safely in any patient. That
`
`testimony is relevant to Petitioner’s argument in the IPR2013-00507 Reply, p. 11
`
`that “implants having these expanded dimensions can, and have been made and
`
`implanted using a postero-lateral technique.” The testimony undermines
`
`Petitioner’s Reply argument by confirming the lack of evidence that a boomerang
`
`implant of the identified confidential dimensions was implanted safely or at all, let
`
`alone using a postero-lateral (TLIF) technique.
`
`Observation #10
`
`In Ex. 2038, on page 91, line 7 to page 93, line 8, Mr. Josse testified that his
`
`principal function working for Petitioner Medtronic over the last 20 years has been
`
`designing implants, that he has designed both interbody fusion spacers and
`
`vertebral body replacement devices, but that he has “no opinion” on whether there
`
`9
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`is a difference between an interbody fusion spacer and a vertebral body
`
`replacement. That testimony again calls into question Mr. Josse’s credibility
`
`because he was unwilling to answer questions regarding the differences between
`
`vertebral body replacements and interbody fusion implants despite his twenty years
`
`of experience designing both.
`
`
`
`
`
`
`Date: 10/6/2014
`
`
`Customer Number 26171
`Fish & Richardson P.C.
`Telephone: (612) 337-2508
`Facsimile: (612) 288-9696
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
` /Stuart A. Nelson/
`Stuart A. Nelson
`Reg. No. 63,947
`
`
`
`10
`
`
`
`Case IPR2013-00506
`Attorney Docket No: 13958-0116IP2
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 CFR §§ 42.6(e)(4) and 42.6(e)(4)(iii), the undersigned
`
`certifies that on October 6, 2014, a complete and entire copy of this Motion for
`
`Observation Regarding Cross-Examination of Loic Josse was provided via email to
`
`the Petitioner by serving the email correspondence address of record as follows:
`
`Jeff E. Schwartz
`Seth A. Kramer
`Fox Rothschild LLP
`1030 15th Street, NW
`Washington, DC 20005
`
`Email: jeschwartz@foxrothschild.com
`Email: skramer@foxrothschild.com
`Email: ipdocket@foxrothschild.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` /Diana Bradley/
`Diana Bradley
`Fish & Richardson P.C.
`3200 RBC Plaza
`60 South Sixth Street
`Minneapolis, MN 55402
` (858) 678-5667
`
`
`
`11
`
`